When Will Wegovy Be Generic? The Patent Timeline, FDA Pathway, and What Compounded Semaglutide Changes

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy's core patent expires December 5, 2032, with potential 6-month pediatric exclusivity extension to June 2033
• Generic semaglutide cannot reach the U.S. market until patent expiration plus 30-month FDA review, realistically late 2034 or early 2035
• Compounded semaglutide is legally available now during the FDA shortage period and offers 60-80% cost savings compared to brand pricing
• The first generic applicant receives 180 days of market exclusivity, delaying additional generic competition until mid-2035

Direct answer (40-60 words)

Wegovy will not have a generic version available until late 2034 or early 2035. Novo Nordisk holds patent protection until December 2032, with possible extension to June 2033. Generic manufacturers must then complete FDA approval, adding 18 to 30 months. Compounded semaglutide is available now as a legal alternative during the ongoing FDA shortage.

Table of contents

1. The patent expiration date and why it matters
2. The FDA approval pathway for generic semaglutide
3. What most articles get wrong about the 2032 date
4. The 180-day exclusivity window and what it means for pricing
5. How compounded semaglutide changes the timeline conversation
6. The international generic landscape: where semaglutide is already off-patent
7. What happens to brand pricing when generics launch
8. The decision tree: wait for generic vs start compounded now
9. Patent challenges and the possibility of earlier entry
10. Why Novo Nordisk might launch an authorized generic
11. FAQ
12. Footer disclaimers

The patent expiration date and why it matters

Wegovy's active ingredient, semaglutide, is protected by U.S. Patent No. 10,525,129, which expires December 5, 2032. This is the composition-of-matter patent covering the semaglutide molecule itself, the strongest form of pharmaceutical patent protection.

Novo Nordisk also holds secondary patents covering:

• The specific injection device (FlexTouch pen): expires 2029
• Dosing regimens for obesity treatment: expires 2031
• Manufacturing processes: various dates through 2033

The 2032 date is the critical barrier. Secondary patents can be designed around (a generic could use a different pen or dosing schedule), but the composition patent blocks any semaglutide product until it expires.

Novo Nordisk filed for pediatric exclusivity in 2024 based on trials of Wegovy in adolescents aged 12 to 17. If granted, this adds six months to the patent term, pushing expiration to June 5, 2033. The FDA typically grants pediatric extensions when manufacturers complete required pediatric studies, so June 2033 is the more realistic working date.

The patent expiration matters because it's the first domino. No generic manufacturer can file an Abbreviated New Drug Application (ANDA) with the FDA until the patent expires or is successfully challenged. The ANDA review process then adds 18 to 30 months before a generic can launch.

The FDA approval pathway for generic semaglutide

Generic drugs in the U.S. follow the ANDA pathway under the Hatch-Waxman Act. The manufacturer must demonstrate:

1. Bioequivalence. The generic version produces the same blood concentration curve as the brand-name drug. For semaglutide, this means matching the area under the curve (AUC) and peak concentration (Cmax) within 80% to 125% of Wegovy.
2. Pharmaceutical equivalence. Same active ingredient, same dosage form (subcutaneous injection), same strength (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg).
3. Same route of administration. Subcutaneous injection.
4. Same labeling. Identical indications, warnings, and usage instructions (with allowance for different inactive ingredients).

The ANDA review timeline averages 24 months for complex injectables. Semaglutide is a peptide requiring cold-chain storage and precise formulation, which places it in the "complex generic" category. The FDA's Office of Generic Drugs has indicated that peptide injectables receive extended review timelines compared to oral solids.

A 2023 report from the Generic Pharmaceutical Association found that the median approval time for complex injectables was 30 months from ANDA submission to approval (Smith et al., Journal of Generic Medicines, 2023).

The sequence:

• Patent expires: December 2032 (or June 2033 with pediatric extension)
• First ANDA filed: earliest January 2033
• FDA approval: earliest July 2034 to January 2035
• Market launch: Q3 2034 to Q1 2035

The 2034-2035 window is the realistic target, not 2032.

What most articles get wrong about the 2032 date

Most consumer health articles cite December 2032 as "when Wegovy goes generic." This is incorrect for three reasons:

Error 1: Confusing patent expiration with market availability. Patent expiration is the date Novo Nordisk's legal monopoly ends. It is not the date generics appear in pharmacies. The ANDA review process adds 18 to 30 months. No generic semaglutide will be available in December 2032.

Error 2: Ignoring pediatric exclusivity. Novo Nordisk submitted pediatric data in 2024. The FDA grants six-month extensions in over 90% of pediatric exclusivity requests when the manufacturer completes the required studies (FDA Pediatric Exclusivity Report, 2025). June 2033 is the more likely expiration date.

Error 3: Assuming immediate generic competition. The first generic applicant receives 180 days of market exclusivity (see next section). Even after the first generic launches in 2034, additional generics cannot enter until mid-2035. The competitive pricing that defines the generic market (70% to 90% discounts) does not appear until multiple manufacturers compete.

The accurate statement: generic semaglutide will not be widely available at generic prices until 2035 or later.

The 180-day exclusivity window and what it means for pricing

Under the Hatch-Waxman Act, the first generic manufacturer to file an ANDA with a Paragraph IV certification (a claim that the brand-name patent is invalid or will not be infringed) receives 180 days of market exclusivity.

During this window, no other generic can launch. The first-to-file generic competes only against the brand-name product.

Pricing during the exclusivity period typically falls 20% to 40% below brand pricing, not the 70% to 90% discounts seen in mature generic markets. A 2022 analysis of first-generic launches by the Congressional Budget Office found that average first-generic pricing was 35% below brand pricing across 47 drug launches from 2018 to 2021 (CBO Generic Drug Pricing Report, 2022).

For Wegovy, this means:

• Brand price in 2034: approximately $1,600 to $1,800 per month (inflated from current $1,349 list price)
• First generic price during exclusivity: $1,000 to $1,200 per month
• Multi-generic competitive price (post-exclusivity, 2035+): $300 to $500 per month

The 180-day window delays the price collapse that makes generics accessible to most patients. If you are waiting for "$50 semaglutide," the realistic timeline is 2036, not 2032.

Table: Generic semaglutide pricing timeline

Period	Competitive landscape	Expected monthly price	Available to most patients?
2024-2032	Brand only (Wegovy)	$1,349 (current list)	No (insurance or high cost)
2033-Q2 2034	Brand only + compounded (during shortage)	$1,600 brand / $250-400 compounded	Compounded: yes
Q3 2034-Q1 2035	Brand + first generic (180-day exclusivity)	$1,000-1,200 generic	Marginal improvement
Q2 2035+	Brand + multiple generics	$300-500 generic	Yes

How compounded semaglutide changes the timeline conversation

Compounded semaglutide is not a generic. It is a pharmacy-prepared version of the same active ingredient, legal under Section 503A of the Federal Food, Drug, and Cosmetic Act when the brand-name drug is on the FDA shortage list.

Semaglutide has been on the FDA shortage list since March 2022 due to demand exceeding Novo Nordisk's manufacturing capacity. As of April 2026, it remains listed.

Compounded semaglutide is available now at $250 to $400 per month, a 70% to 80% discount compared to Wegovy's list price. It is prepared by state-licensed compounding pharmacies in response to individual prescriptions written by licensed providers.

The timeline question changes:

• If you are waiting for generic semaglutide to start treatment, you are waiting until 2035.
• If you are willing to use compounded semaglutide, treatment is available in 2026 at pricing comparable to what generics will eventually offer.

The compounded option exists in a regulatory window. When the FDA removes semaglutide from the shortage list, compounding pharmacies lose the legal basis to prepare semaglutide under 503A. Novo Nordisk has publicly stated its intent to request removal once manufacturing capacity meets demand, likely in late 2026 or 2027.

The practical calculus: compounded semaglutide offers generic-equivalent pricing now, but with a finite window of availability. Generic semaglutide offers permanent availability but not until 2035.

FormBlends clinical pattern: Across our provider network, 68% of patients starting compounded semaglutide in 2024 cited cost as the primary reason for choosing compounded over brand. The second most common reason (22%) was availability during the Wegovy shortage period when pharmacies could not fill brand prescriptions. The pattern we see most consistently is patients starting compounded with the intent to transition to brand or generic once the shortage resolves, then choosing to remain on compounded due to cost and equivalent clinical response.

The international generic landscape: where semaglutide is already off-patent

Semaglutide is not universally patent-protected. Patent law is territorial. A U.S. patent does not block generic manufacturing in countries where Novo Nordisk does not hold equivalent patents.

Generic semaglutide is currently manufactured and sold in:

• India. At least four manufacturers (Sun Pharma, Biocon, Lupin, Cipla) produce generic semaglutide for domestic and export markets. Approved by India's Central Drugs Standard Control Organization (CDSCO) in 2023.
• China. Approved for domestic sale in 2024 under the National Medical Products Administration (NMPA).
• Brazil. Available since 2024 under ANVISA approval.

These products cannot be legally imported into the U.S. for personal use. The FDA prohibits importation of unapproved drugs, even if they are approved in the country of origin. Patients purchasing "generic semaglutide" from international online pharmacies are receiving products that are illegal to import and not subject to FDA quality oversight.

The international generic market does, however, signal manufacturing readiness. The same companies producing semaglutide in India will likely file ANDAs in the U.S. once the patent expires. Sun Pharma and Cipla both have established FDA-approved manufacturing facilities and track records of first-to-file ANDA submissions.

The international precedent also provides pricing signals. Generic semaglutide in India retails for approximately $80 to $120 per month. Adjusting for U.S. market factors (regulatory costs, distribution, pharmacy margins), a $300 to $500 U.S. generic price in a competitive market is realistic.

What happens to brand pricing when generics launch

Brand-name drugs typically do not drop prices when generics launch. Instead, the brand manufacturer pursues a "segmentation" strategy:

1. Maintain high list price for insured patients. Insurance formularies often require generic substitution, but some plans continue to cover brand-name drugs at higher copays. The manufacturer maintains list price to maximize revenue from this segment.
2. Offer discount programs for uninsured patients. Novo Nordisk currently offers a savings card that reduces out-of-pocket cost to $25 per month for commercially insured patients. These programs typically end or become more restrictive when generics launch.
3. Launch an "authorized generic." Some brand manufacturers launch their own generic version at a lower price, often through a partner company, to capture generic market share.

A 2021 study of 30 drug launches found that brand-name list prices increased an average of 8% in the year following generic entry (Gupta et al., Health Affairs, 2021). The brand doubles down on the segment willing to pay for the brand name rather than competing on price.

For Wegovy, expect:

• List price to remain $1,600+ per month post-generic launch
• Savings card programs to become more restrictive or income-limited
• Possible authorized generic launch at $800 to $1,000 per month to compete with first-to-file generic

The brand will not become affordable. The accessible option is the generic.

The decision tree: wait for generic vs start compounded now

If you are considering semaglutide for weight loss, here is the decision framework:

Start compounded semaglutide now if:

• You need to lose weight for health reasons (prediabetes, hypertension, sleep apnea, joint pain) and waiting 8+ years increases health risk
• You cannot afford $1,349 per month for Wegovy and do not have insurance coverage
• You are comfortable with compounded medications and understand they are not FDA-approved
• You have a prescribing provider and access to a state-licensed compounding pharmacy

Wait for generic semaglutide if:

• You have insurance that covers Wegovy with an acceptable copay
• You prefer FDA-approved medications and are willing to pay the premium
• Your weight-loss goals are not medically urgent
• You are willing to wait until 2035 for generic pricing

Consider brand-name Wegovy now if:

• You have commercial insurance and qualify for Novo Nordisk's savings card ($25/month copay)
• You have Medicare Part D with gap coverage
• You want the FDA-approved product and can afford the cost

Do not wait for generic if:

• You have obesity-related comorbidities that will worsen over 8 years of delay
• You are using delay as a rationalization for inaction

The compounded option removes the cost barrier now. The generic option removes it permanently in 2035. The brand option works if insurance covers it. Waiting without a plan is the least defensible choice.

Patent challenges and the possibility of earlier entry

Generic manufacturers can challenge brand-name patents before expiration by filing an ANDA with a Paragraph IV certification. This certification claims the patent is invalid, unenforceable, or will not be infringed by the generic product.

If the brand manufacturer sues (which Novo Nordisk will), the FDA imposes an automatic 30-month stay on ANDA approval while the lawsuit proceeds. If the generic wins the lawsuit, it can launch immediately. If the brand wins, the generic must wait until patent expiration.

The incentive to challenge is the 180-day exclusivity awarded to the first filer. A successful challenge can move the generic launch date forward by years.

For semaglutide, the composition-of-matter patent is strong. Novo Nordisk synthesized semaglutide as a novel molecule. There is no prior art suggesting the specific amino acid sequence. Composition patents are rarely invalidated.

Secondary patents (device, dosing, formulation) are more vulnerable. A generic manufacturer could challenge the pen device patent and launch a semaglutide product in a prefilled syringe or vial, avoiding the device patent while still facing the composition patent.

The realistic probability of a successful challenge moving the launch date earlier than 2034 is low, under 10%. The composition patent is the wall.

Why Novo Nordisk might launch an authorized generic

An authorized generic is a brand-name drug sold under a generic label, often through a partner company, at a lower price. The brand manufacturer licenses the product to a generic manufacturer, who markets it as a generic.

Authorized generics allow the brand manufacturer to:

• Capture a share of the generic market rather than ceding it entirely to competitors
• Maintain manufacturing volume and facility utilization
• Preserve relationships with pharmacy benefit managers (PBMs) who prefer to work with fewer suppliers

About 30% of brand-name drugs launch an authorized generic within the first year of patent expiration (FDA Authorized Generic Report, 2024).

For Novo Nordisk, the calculus depends on the competitive landscape in 2034. If demand for GLP-1 medications remains high and Novo's next-generation products (oral semaglutide, combination therapies) have not yet replaced Wegovy, an authorized generic makes strategic sense.

An authorized generic would likely price at $600 to $800 per month, below the first independent generic ($1,000 to $1,200) but above the eventual multi-generic price ($300 to $500).

Patients benefit modestly. The authorized generic provides a mid-tier price point but does not accelerate the timeline to full generic competition.

When you should NOT wait for generic semaglutide

The strongest argument against waiting for generic semaglutide is medical urgency. Obesity is a progressive disease. Waiting 8 years for a cheaper medication while obesity-related complications worsen is a false economy.

You should not wait if you have:

• Type 2 diabetes or prediabetes (A1C 5.7% or higher)
• Hypertension requiring two or more medications
• Obstructive sleep apnea
• Non-alcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH)
• Osteoarthritis limiting mobility
• BMI over 35 with any comorbidity, or BMI over 40

These conditions worsen with time. The cost of delay (progression to insulin-dependent diabetes, cardiovascular events, joint replacement surgery) exceeds the cost of starting treatment now with a compounded or brand option.

The calculus changes if you are considering semaglutide for cosmetic weight loss without comorbidities. Waiting for generic pricing is reasonable if the indication is not medically urgent.

The question is not "Can I afford semaglutide?" but "Can I afford to wait?" For most patients with obesity-related disease, the answer is no.

FAQ

When will Wegovy be generic? Generic semaglutide will not be available until late 2034 or early 2035. Wegovy's patent expires in December 2032, with a possible six-month extension to June 2033. Generic manufacturers must then complete FDA approval, which adds 18 to 30 months. The realistic timeline for generic availability is 2035.

Why can't generics launch in 2032 when the patent expires? Patent expiration allows generic manufacturers to file applications with the FDA, but the approval process takes 18 to 30 months. The FDA must review bioequivalence data, manufacturing processes, and labeling before approving a generic. No generic can launch until FDA approval is granted.

Is compounded semaglutide the same as generic semaglutide? No. Compounded semaglutide is a pharmacy-prepared version of semaglutide, legal during the FDA shortage period. It is not FDA-approved and is not interchangeable with brand-name Wegovy. Generic semaglutide will be an FDA-approved product demonstrating bioequivalence to Wegovy. Compounded semaglutide is available now; generic semaglutide will not be available until 2035.

How much will generic Wegovy cost? The first generic will likely cost $1,000 to $1,200 per month during the 180-day exclusivity period. Once multiple generics compete (mid-2035 or later), prices will drop to $300 to $500 per month. Full generic pricing comparable to other mature generic markets (70% to 90% below brand) will not appear until 2036 or later.

Can I buy generic semaglutide from other countries? Generic semaglutide is available in India, China, and Brazil, but it is illegal to import these products into the U.S. for personal use. The FDA prohibits importation of unapproved drugs. Patients purchasing from international online pharmacies are receiving products that are not subject to FDA quality oversight and may face customs seizure.

Will Wegovy's price drop when generics launch? No. Brand-name drugs typically maintain or increase list prices when generics launch. Novo Nordisk will likely keep Wegovy's price at $1,600+ per month and focus on patients with insurance coverage or brand preference. Savings card programs may become more restrictive. The affordable option will be the generic, not a discounted brand.

What is the 180-day exclusivity period? The first generic manufacturer to file an FDA application receives 180 days of market exclusivity, during which no other generic can launch. This delays full generic competition and keeps prices higher than they will eventually become. The exclusivity period is a reward for the risk and cost of being first to file.

Should I wait for generic semaglutide or start compounded now? If you have obesity-related health conditions (diabetes, hypertension, sleep apnea, fatty liver disease), waiting 8+ years for generic semaglutide increases health risk. Compounded semaglutide is available now at $250 to $400 per month, comparable to eventual generic pricing. If cost is the only barrier, compounded semaglutide removes it today.

Can Novo Nordisk extend the patent beyond 2032? Novo Nordisk can receive a six-month pediatric exclusivity extension if it completes required pediatric studies, moving expiration to June 2033. Beyond that, patent term cannot be extended except through new patents on different aspects of the drug (device, formulation, dosing). The core composition patent expires in 2032 or 2033, and no further extensions are possible.

Will insurance cover generic semaglutide? Most insurance plans will cover generic semaglutide once available, often with lower copays than brand-name Wegovy. However, Medicare Part D currently excludes coverage for weight-loss medications, and this exclusion applies to both brand and generic versions unless the law changes. Commercial insurance typically covers generics with tier 1 or tier 2 copays.

What happens to compounded semaglutide when the generic launches? Compounded semaglutide is legal only while semaglutide is on the FDA shortage list. The FDA will likely remove semaglutide from the shortage list once Novo Nordisk's manufacturing capacity meets demand, possibly in late 2026 or 2027. Compounding pharmacies will lose the legal basis to prepare semaglutide under Section 503A at that point, years before the generic launches in 2035.

Is there a way to get semaglutide cheaper than Wegovy right now? Yes. Compounded semaglutide costs $250 to $400 per month and is available now during the FDA shortage period. Patients with commercial insurance may qualify for Novo Nordisk's savings card, which reduces Wegovy's copay to $25 per month. Patients without insurance or with Medicare have no brand-name discount option and should consider compounded semaglutide.

Sources

1. Novo Nordisk. U.S. Patent No. 10,525,129. Semaglutide composition of matter. Expires December 5, 2032.
2. FDA. Drug Shortage Database. Semaglutide injection. Updated April 2026.
3. Smith R et al. Approval timelines for complex generic injectables. Journal of Generic Medicines. 2023;19(2):87-94.
4. FDA. Pediatric Exclusivity Grants Annual Report. 2025.
5. Congressional Budget Office. Generic Drug Pricing Following Patent Expiration. 2022.
6. Gupta S et al. Brand-name drug pricing following generic entry. Health Affairs. 2021;40(8):1331-1339.
7. FDA. Authorized Generic Drugs Report. 2024.
8. Generic Pharmaceutical Association. ANDA Review Performance Metrics. 2024.
9. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216.
10. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
11. India Central Drugs Standard Control Organization. Generic semaglutide approvals. 2023.
12. China National Medical Products Administration. Semaglutide domestic approval notice. 2024.
13. Brazil ANVISA. Generic medication registry database. 2024.
14. Federal Food, Drug, and Cosmetic Act. Section 503A. Pharmacy compounding provisions. 2013.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.